Breast Cancer

An exploratory TROPION-Breast02 analysis showed CNS PFS and intracranial response benefits with datopotamab deruxtecan in TNBC with brain metastases.

Abemaciclib plus fulvestrant showed a numerical yet nonsignificant overall survival trend after CDK4/6 inhibitor progression in final postMONARCH data.

Selective CDK4 inhibitor atirmociclib plus fulvestrant reduced risk of progression or death by 40% vs investigator's choice of therapy in the phase 2 FOURLIGHT-1 trial.

Signifcant efficacy improvements were shown with iza-bren in HR+/HER2-negative breast cancer.

A protein called MPP8 helps drive chemotherapy resistance in the most-aggressive subtype of breast cancer, and suppressing its expression has the potential to improve treatment outcomes.

Breast cancer experts address frequently asked questions on adjuvant and metastatic CDK4/6 inhibitor selection in HR-positive breast cancer.

The 510(k) clearance covers an MRI-derived AI risk score for stage I to IIIA disease; the high-risk category carried an HR of 2.81 for recurrence.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.

Nunnery and Bond discuss how patients and advocates can navigate second opinions, mental health support, and the long-term effects of cancer treatment.

Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.

Matthew P. Goetz, MD, explores menopausal status, recurrence risk, and adjuvant CDK4/6 inhibitor selection in HR-positive breast cancer.

Matthew P. Goetz, MD, explores first-line treatment selection, emerging targeted therapies, and unmet sequencing needs in metastatic breast cancer.

Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.

The top 5 OncLive TV videos of the week.

The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

China's approval of Dato-DXd for TNBC was supported by TROPION-Breast02 data showing a median OS of 23.7 months vs 18.7 months with chemotherapy.

Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.

The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.

The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.

Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.

Denosumab-adet (Degevma) is FDA-approved as an Xgeva biosimilar for SRE prevention in myeloma and bone metastases, giant cell tumor of bone, and hypercalcemia of malignancy.